ArticleBMC complementary medicine and therapies2026
Saxifraga stolonifera curtis for ear inflammation: antibacterial efficacy and key bioactive constituents.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSaxifraga stolonifera Curtis (SSC), a highly esteemed Traditional Chinese Medicine with profound ethnomedicinal value, has been historically employed to treat inflammatory ear disorders. Contemporary preclinical studies have verified its effectiveness in combating otitis media (OM). However, the underlying pharmacological mechanisms, particularly its anti-inflammatory and antibacterial properties remain unclear. PURPOSE: This study aimed to systematically elucidate the chemical basis, antibacterial activity and molecular mechanisms underlying SSC’s anti-OM activity.
methodsUHPLC-Q-TOF-MS was employed for comprehensive phytochemical profiling of SSC total extracts. Antibacterial assays were conducted against three OM-associated bacterial strains: Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA), and Klebsiella pneumoniae (KP), using SSC total extracts and its total flavonoid (TF). Network pharmacology analysis identified OM-related targets and pathways, followed by molecular docking validation. qPCR was used to assess mRNA expression of inflammatory cytokines (IL-6, TNF-α, IL-1β) in LPS-induced J774A.1 macrophages.
resultsTwenty-five bioactive compounds were characterized, including 11 newly reported constituents. Antibacterial results showed SSC exhibited the strongest inhibitory effect against KP, while TF showed relatively strong activity against PA; overall, SSC outperformed TF, suggesting contributions from non-flavonoid components. Network pharmacology revealed 11 core targets interconnected with inflammatory pathways. Molecular docking confirmed strong binding affinities between key components (bergenin, 11-O-galloylbergenin) and targets (HSP90AA1, EGFR). SSC total extracts significantly downregulated pro-inflammatory cytokine mRNA levels in vitro.
conclusionSSC exerts anti-OM effects through a “dual mechanism”: antibacterial activity (with SSC total extract showing stronger efficacy than TF) and anti-inflammatory regulation via TNF/MAPK/NF-κB pathways. This integrative study validates SSC’s traditional use and provides a basis for developing SSC-based therapeutics for OM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.